Biohaven Pharmaceutical Holding Company Ltd.

When Michael Davidson, CEO of NewAmsterdam Pharma, describes his company’s lead asset obicetrapib, he frames it as a solution to one of cardiology’s most persistent challenges: managing residual cardi

After pulling back on M&A last year to digest the $43bn acquisition of Seagen in 2023, Pfizer said it is in a position to complete bigger deals this year, but that the company will be strategic ab

The market for initial public offerings in the US heated up in September with five biopharmaceutical companies launching IPOs, the second busiest month for first-time offerings in 2024 after there wer

Scholar Rock, LLC unveiled Phase III data on 7 October that appears to make a strong case for its selective myostatin inhibitor apitegromab as additive therapy that can improve motor function in pati